Table 3.
Study 1 and study 2 blood pressure and vascular function
|
Study 1 |
Study 2 |
|||
|---|---|---|---|---|
| Placebo | Nitrate | Placebo | Nitrate | |
| Blood pressure | ||||
| SBP, mmHg | 132 ± 20 | 129 ± 16 | 141 ± 19 | 136 ± 16† |
| DBP, mmHg | 78 ± 12 | 77 ± 12 | 88 ± 12 | 84 ± 13† |
| MAP, mmHg | 96 ± 12 | 94 ± 11 | 106 ± 13 | 101 ± 12† |
| PLM | ||||
| Baseline LVC, mL·min−1·mmHg−1 | 2.9 ± 0.9 | 3.2 ± 1.2 | 2.7 ± 1.0 | 3.1 ± 0.8 |
| ΔLVCpeak, mL·min−1·mmHg−1 | 6.0 ± 2.6 | 6.2 ± 2.5 | 5.1 ± 2.6 | 6.0 ± 3.0† |
| FMD | ||||
| Baseline diameter, mm | 4.6 ± 0.8 | 4.7 ± 0.9 | 4.7 ± 0.8 | 4.7 ± 0.9 |
| FMD, % | 3.6 ± 2.8 | 4.7 ± 2.3 | 4.1 ± 2.7 | 6.1 ± 2.4† |
| Total sum of shear, AU | 73,038 ± 63,974 | 64,810 ± 43,932 | 62,515 ± 51,417 | 69,871 ± 46,961 |
| Reactive hyperemia, mL | 605 ± 196 | 656 ± 310 | 574 ± 268 | 635 ± 239 |
Data are means ± SD. Study 1: n = 13 for all variables. Study 2: n = 14 for all variables. ΔLVCpeak, peak change in LVC above baseline; AU, arbitrary units; DBP, diastolic blood pressure; FMD, flow-mediated dilation; LVC, leg vascular conductance; MAP, mean arterial blood pressure; PLM, passive leg movement; SBP, systolic blood pressure.
†
Different from placebo within study (P < 0.05).